2. Search Result
Search Result
Isoforms Recommended: TNKS2/PARP5B
Results for "

TNKS2

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

4

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-156332
    TNKS-2-IN-2

    		PARP Cancer
    TNKS-2-IN-2 is a potent and selective inhibitor of TNKS2 with an IC50 of 22 nM .
    TNKS-2-IN-2
  • HY-23338
    TNKS-2-IN-1

    		PARP Others
    TNKS-2-IN-1 (Compound 13g) is a TNKS-2 inhibitor. TNKS-2-IN-1 inhibits TNKS-1 and TNKS-2 with IC50s of 259 nM and 1100 nM .
    TNKS-2-IN-1
  • HY-143338
    ART-IN-1

    		PARP Cancer
    ART-IN-1 (compound 7) is a selective PARP inhibitor with IC50s of 19, 22, 2.4, >100, 1.1 µM for PARP2, TNKS2, PARP10, PARP14, PARP15, respectively .
    ART-IN-1
  • HY-12418
    Stenoparib
    1 Publications Verification

    E7449; 2X-121

    		 PARP Cancer
    Stenoparib (E7449) is a potent PARP1 and PARP2 inhibitor and also inhibits TNKS1 and TNKS2, with IC50s of 2.0, 1.0, ∼50 and ∼50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using 32P-NAD + as substrate.
    Stenoparib
  • HY-121719
    TIQ-A

    		PARP Cardiovascular Disease Cancer
    TIQ-A is a potent TNKS (poly-ART, PARP) inhibitor, with an IC50 of 24 nM for TNKS2. TIQ-A is a potential anti-ischemic agent .
    TIQ-A
  • HY-12438
    G007-LK
    5+ Cited Publications

    		 PARP Cancer
    G007-LK is a potent and selective inhibitor of TNKS1 and TNKS2, with IC50s of 46 nM and 25 nM, respectively.
    G007-LK
  • HY-RS14843
    TNKS2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TNKS2 Human Pre-designed siRNA Set A contains three designed siRNAs for TNKS2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNKS2 Human Pre-designed siRNA Set A
    TNKS2 Human Pre-designed siRNA Set A
  • HY-RS14844
    Tnks2 Mouse Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    Tnks2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Tnks2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

    Tnks2 Mouse Pre-designed siRNA Set A
    Tnks2 Mouse Pre-designed siRNA Set A
  • HY-RS14845
    TNKS2 Rat Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TNKS2 Rat Pre-designed siRNA Set A contains three designed siRNAs for TNKS2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNKS2 Rat Pre-designed siRNA Set A
    TNKS2 Rat Pre-designed siRNA Set A
  • HY-12601
    TNKS 22

    TNKS-IN-22

    		 PARP Cancer
    TNKS 22 (compound 22) is an orally active and selective tankyrase inhibitor. TNKS 22 inhibits TNKS1 and TNKS2 with IC50s of 0.1 and 4.1 nM, respectively .
    TNKS 22
  • HY-16910
    WIKI4
    2 Publications Verification

    		 PARP β-catenin Cancer
    WIKI4 is a potent tankyrase inhibitor with an IC50 of 26 nM for TNKS2. WIKI4 potently inhibits Wnt/β-catenin signaling and that its half-maximal response dose is 75 nM. WIKI4 mediates its effects on Wnt/β-catenin signaling by inhibiting the enzymatic activity of TNKS2 [2]. WIKI4 is cytotoxic to SCLC cells with an IC50 value of 0.02 μM .
    WIKI4
  • HY-13990
    NVP-TNKS656

    TNKS656

    		 PARP Apoptosis Cancer
    NVP-TNKS656 is a highly potent, selective, and orally active TNKS2 inhibitor with IC50 of 6 nM, and is > 300 fold selectivity against PARP1 and PARP2.
    NVP-TNKS656
  • HY-U00422
    K-756
    2 Publications Verification

    		 PARP Cancer
    K-756 is a direct and selective tankyrase (TNKS) inhibitor, which inhibits the ADP-ribosylation activity of TNKS1 and TNKS2 with IC50s of 31 and 36 nM, respectively.
    K-756
  • HY-15147
    XAV-939
    Maximum Cited Publications
    129 Publications Verification

    		 β-catenin PARP Cancer
    XAV-939 is a Tankyrase inhibitor. XAV-939 has inhibitory activity for TNKS1 and TNKS2 with IC50 values of 5 nM and 2 nM, respectively. XAV-939 also is an enhancer of osteoblastic differentiation of hMSCs. XAV-939 can be used for the research of conditions associated with activated Wnt signaling, such as cancer, fibrotic diseases and conditions associated with low bone formation [2] .
    XAV-939
  • HY-19351
    MN-64
    3 Publications Verification

    		 PARP Cancer
    MN-64 is a potent tankyrase 1 inhibitor, with IC50s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for TNKS1, TNKS2, ARTD1 and ARTD2, respectively.
    MN-64
  • HY-153332
    Tankyrase-IN-5

    		PARP Cancer
    Tankyrase-IN-5 (Compound 30f), an analogue of MSC2504877 (HY-123851), is a tankyrase TNKS1 and TNKS2 inhibitor with IC50s of 2.3 nM and 7.9 nM, respectively .
    Tankyrase-IN-5
  • HY-146336
    PARP1/2/TNKS1/2-IN-1

    		PARP Apoptosis Cancer
    PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual PARP-1, PARP-2, TNKS1 and TNKS2 inhibitor with IC50 values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .
    PARP1/2/TNKS1/2-IN-1
  • HY-147886
    PARP1-IN-11

    		PARP Cancer
    PARP1-IN-11 (compound 49) is a potent PARP1 inhibitor with IC50 value of 0.082 µM. PARP1-IN-11 shows complete inhibition of PARP2 and substantially inhibits PARP3, TNKS1 and TNKS2 .
    PARP1-IN-11
  • HY-126248
    Tankyrase-IN-2

    		PARP Cancer
    Tankyrase-IN-2 (compound 5k) is a potent, selective, and orally active tankyrase inhibitor (IC50s of 10, 7, and 710 nM for TNKS1, TNKS2 as well as PARP1, respectively). Tankyrase-IN-2 has favorable physicochemical profile and pharmacokinetic properties modulating Wnt pathway activity in a colorectal xenograft model .
    Tankyrase-IN-2
  • HY-12975
    AZ6102
    1 Publications Verification

    		 PARP Cancer
    AZ6102 is a potent dual TNKS1 and TNKS2 inhibitor, with IC50s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC50s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.
    AZ6102
  • HY-123851
    MSC2504877

    M2912

    		 PARP Cancer
    MSC2504877 (M2912) is a potent and orally active tankyrase inhibitor with IC50s of 0.0007, 0.0008, 0.54 µM for TNKS, TNKS2, PARP1, respectively. MSC2504877 increases the expression of AXIN2 and TNKS protein levels and decreases β-catenin levels. MSC2504877 shows anti-tumor activity .
    MSC2504877
  • HY-100847
    AZ0108

    		PARP Cancer
    AZ0108 is an inhibitor for poly ADP-ribose polymerase (PARP), which inhibits PARP1, PARP2, PARP3, PARP6, TNKS1, TNKS2, with IC50s of <0.03, <0.03, 2.8, 0.083, 3.2, >3 μM, respectively. AZ0108 prevents centrosome clustering with an EC50 of 0.053 μM, and exhibits cytotoxicity in cell OCI-LY-19 with GI50 of 0.017 μM. AZ0108 exhibits good in vivo pharmacokinetic characters in rat/mouse models .
    AZ0108
  • HY-145111
    TNK2-IN-1

    		Tyrosinase Cancer
    TNK2-IN-1 is a TNK2 inhibitor. TNK2-IN-1 has an IC50 of 224 nM for TNK2. TNK2-IN-1 can be used for the research of cancer .
    TNK2-IN-1
  • HY-RS14838
    TNK2 Human Pre-designed siRNA Set A

    		Small Interfering RNA (siRNA) Others

    TNK2 Human Pre-designed siRNA Set A contains three designed siRNAs for TNK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    TNK2 Human Pre-designed siRNA Set A
    TNK2 Human Pre-designed siRNA Set A
  • HY-15811
    XMD8-87

    ACK1-B19

    		 Tyrosinase Cancer
    XMD8-87 is a potent TNK2 inhibitor with IC50 values of 38 and 113 nM for the D163E and R806Q mutations, respectively.
    XMD8-87
  • HY-101243
    XMD16-5

    		Tyrosinase Cancer
    XMD16-5 is a potent TNK2 inhibitor with IC50 values of 16 and 77 nM for the D163E and R806Q mutations, respectively.
    XMD16-5
  • HY-153259
    TNKS1/2-IN-2

    		PARP Cancer
    TNKS1/2-IN-2 (Compound 21) is a potent and selective tankyrases inhibitor. TNKS1/2-IN-2 exhibits IC50 values of 4 nM and 63 nM against TNK1 and TNK2 in the enzymatic assay, respectively. TNKS1/2-IN-2 inhibits proliferation of A549 and H292 cell lines with IC50 values of 39.5 nM and 12.8 nM, respectively. TNKS1/2-IN-2 can be used for the research of cancer .
    TNKS1/2-IN-2
  • HY-145267
    OM-153

    		PARP Wnt Cancer
    OM-153 is a potent and orally active tankyrase inhibitor with IC50s of 13 nM and 2 nM for tankyrase 1 and tankyrase 2 (TNKS1/2), respectively. OM-153 inhibits luciferase-based Wnt/β-catenin signaling reporter activity with an IC50 value of 0.63 nM. OM-153 shows inhibition of Wnt/β-catenin signaling and proliferation in COLO 320DM [2].
    OM-153
  • HY-145266
    OM-1700

    		PARP Cancer
    OM-1700 is a potent tankyrase inhibitor with IC50s of 127 and 14 nM for tankyrase 1 and tankyrase 2, respectively. OM-1700 reduces cell growth in the colon cancer cell line COLO 320DM (GI50=650 nM) .
    OM-1700
  • HY-148065
    FMF-06-098-1

    		PROTACs Cancer
    FMF-06-098-1 is a multitargeted depressant. FMF-06-098-1 can be used to target degradation kinases which degrades AAK1, AΒL2, AURKA, AURKB, BUBIB, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDk6, CDK7, CDK9, CHEK1, CSNKID, EPHA1, PER, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, S1K2, STK35, TNK2, UHMK1, ULK1, and WEE1 .
    FMF-06-098-1
  • HY-148061
    DB1113

    		PROTACs Bcr-Abl CDK Salt-inducible Kinase (SIK) Cyclin G-associated Kinase (GAK) MAP4K MAPKAPK2 (MK2) Ferroptosis ULK LIM Kinase (LIMK) Others
    DB1113 (Example 24) is a bifunctional compound targeted protein degradation of kinases. DB1113 degrades ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2, and ULK1. DB1113 can be used for research of disease or disorder mediated by aberrant kinase activity .
    DB1113
  • HY-148063
    DB0614

    		PROTACs AAK1 Aurora Kinase CaMK CDK Ferroptosis Salt-inducible Kinase (SIK) LIM Kinase (LIMK) ULK Metabolic Disease
    DB0614 is a PROTAC based on Cereblon ligand, which is a selective and potent targeted protein degrader of NEK9 inhibitor. DB0614 can degrade ABL1, ABL2, BLK, CDK11B, CDK4, CSK, EPHA3, FER, GAK, LIMK1, MAP3K20, MAP4K1, MAP4K2, MAP4K3, MAP4K5, MAPK14, MAPK7, MAPK8, MAPK9, MAPKAPK2, MAPKAPK3, NLK, PDIK1L, PTK2B, RIPK1, RPS6KA1, RPS6KA3, SIK2, SIK3, STK35, TNK2 and ULK1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity [2].(Blue: Thalidomide-4-OH (HY-103596), Black: linker, Pink: FLT3-IN-17 (HY-148070))
    DB0614

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: